ASCO19: smoldering multiple myeloma – can lenalidomide slow its progression?

Researchers have revealed that lenalidomide treatment significantly reduces the risk of precancerous smoldering multiple myeloma progressing into overt multiple myeloma in high-risk individuals; this could potentially lead to a novel standard of care and a delay in organ damage. Results from the Phase II/III randomized clinical trial, E3A06, have demonstrated that lenalidomide significantly lowers the risk of precancerous smoldering multiple myeloma (SMM) from developing into cancer in moderate and high-risk individuals; this could lead to a novel standard of care for individuals with SMM, potentially delaying organ damage. Multiple myeloma (MM) can be distinguished from SMM by the presence of...